Using advanced MRI and AI to find early signs of cancer in children with Neurofibromatosis Type 1
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
This study is trying to see if advanced MRI scans and artificial intelligence can help find early signs of cancer in children with Neurofibromatosis Type 1.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 5 Years to 17 Years |
| Sex | All |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT04763109 on ClinicalTrials.gov |
What this trial studies
This pilot trial involves a single-arm intervention using whole-body Magnetic Resonance Imaging (MRI) combined with artificial intelligence to assess the feasibility and predictive value of detecting pre-malignant lesions in pediatric patients diagnosed with Neurofibromatosis Type 1 (NF-1). The study will evaluate scan-rescan reliability and changes in MRI scans over a 12-month period among 15 participants at Cedars-Sinai Medical Center. The goal is to improve early detection of potential malignancies in this high-risk population.
Who should consider this trial
Good fit: Ideal candidates are pediatric patients aged 5 to 17 years with a confirmed diagnosis of Neurofibromatosis Type 1.
Not a fit: Patients who require sedation for imaging or have certain medical implants or claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of cancerous changes in children with Neurofibromatosis Type 1, potentially improving treatment outcomes.
How similar studies have performed: While the use of MRI and AI in detecting lesions is an emerging field, this specific approach in pediatric NF-1 patients is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll. * Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study. Exclusion Criteria: * Requiring sedation for imaging. * Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies * Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards. * Allergy to animal dander or animal-instigated asthma.
Where this trial is running
Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Nicole Baca, MD — Cedars-Sinai Medical Center
- Study coordinator: Clinical Trial Recruitment Navigator
- Email: GroupCancerTrialInformation@cshs.org
- Phone: 3104232133
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.